Business

Biotech, pharma, and money in science

Pfizer R&D illo
Business

Pfizer’s chessmaster: How a top scientist helped invigorate a lumbering drug giant

By Matthew Herper

Eli Lilly insulin
Business

Reining in drug spending: What states can learn from one another

By Priyanka Dayal McCluskey — Boston Globe

Biotech

New Sanofi CEO wants to tap digital technology to improve drug research and sales

By Matthew Herper

Pharmalot

Pharmalittle: Hormone therapy link to breast cancer strengthened; where did Sacklers’ Purdue money end up?

By Elizabeth Cooney

Broad Institute signage
Business

Battleground narrowed in CRISPR patent case between University of California and Broad

By Sharon Begley

Biotech

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

By Adam Feuerstein

Cambridge: Sarepta
Biotech

Sarepta stumbles on FDA rejection of a new drug to treat Duchenne muscular dystrophy

By Adam Feuerstein

STAT SPOTLIGHT
Biotech

Can targeting one protein complex solve multiple diseases? NodThera is betting on it

By Diana Cai

Sarepta - Cambridge -AP
Biotech

As Sarepta awaits approval of new Duchenne drug, big questions hang over therapy already on market

By Adam Feuerstein

Jeffrey Leiden
Biotech

Vertex, known for cystic fibrosis drugs, sets its sights on taming pain

By Jonathan Saltzman — Boston Globe

Marisa Boidi
Biotech

Toddler denied $2.1m gene therapy will now get it for free

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Delayed approval decision raises fears for Vascepa; drug prices snakebit by lack of competition

By Elizabeth Cooney

Vascepa pill handout
Biotech

Amarin now says FDA plans outside panel review of its Vascepa heart drug, delaying approval decision

By Adam Feuerstein

Pharmalot

Pharmalittle: Medicare will cover CAR-T; Trump health care overhaul in the wings

By Elizabeth Cooney

Pharmalot

Pharmalittle: A new scandal for Novartis; opioid distributors offer to settle lawsuits

By Elizabeth Cooney

Pharmalot

Pharmalittle: Pay-to-play clinical trials draw scrutiny; Chinese drug ingredients called U.S. threat

By Elizabeth Cooney

Pharmalot

Pharmalittle: Guardant’s blood test could replace biopsy; Medicare boosts CAR-T coverage

By Elizabeth Cooney

Medicine
The Pharmalot View

Trump proposes importing medicines, but he’s really seeking a quick political hit

By Ed Silverman

Dr. Feng Zhang Broad Inst
Exclusive

The latest CRISPR patent fight is on. So is the mudslinging

By Sharon Begley

Vascepa pill handout
Biotech

An expanded label for Amarin’s fish-oil drug looks more likely, but how fast will profits arrive?

By Adam Feuerstein

Insulin factory - Novo
Pharmalot

New York attorney general probes big three insulin makers over their pricing

By Ed Silverman

Business

The Pfizer-Mylan deal is not quite as it appears

By Matthew Herper

Fat burning
Biotech

We have answers to some of biotech’s burning questions for 2019 — and some new issues to watch

By Adam Feuerstein and Damian Garde

Biotech

A richly funded CRISPR alternative has a reproducibility problem

By Damian Garde

Vertex
Biotech

Vertex Pharmaceuticals’ Jeffrey Leiden to step aside as CEO

By Matthew Herper

Jeff Jonas
Biotech

Sage Therapeutics to pursue high-risk, high-reward plan for experimental depression pill

By Adam Feuerstein

Mental health parity
Biotech

FDA cancels panel review of Intra-Cellular’s schizophrenia drug, causing shares to tumble

By Adam Feuerstein

Charlie Baker
Pharmalot

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

By Ed Silverman

Ear Hair Cells
Biotech

Frequency Therapeutics raises another $62 million

By Jonathan Saltzman — Boston Globe

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy